The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InUroGen Pharma Ltd. (URGN) has announced positive clinical data from its pivotal ENVISION trial for ZUSDURI™ (UGN-102). The drug achieved durable complete responses in patients suffering from recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC). According to the report, the results demonstrated significant efficacy across various risk groups as classified by the EORTC. The company plans to present a detailed recurrence score analysis at the upcoming ASCO-GU 2026 symposium. These findings support ZUSDURI’s potential as a primary treatment option, marking a significant regulatory milestone for the company. Investors view this development as a major catalyst for UroGen's oncology pipeline and future commercial prospects.